Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
30 Leser
Artikel bewerten:
(0)

Cancer Treatment Centers of America at Midwestern Regional Medical Center Earns "Top Performer on Key Quality Measures" Recognition from The Joint Commission

CHICAGO, Oct. 31, 2013 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (Midwestern) was named Top Performer on Key Quality Measures® by The Joint Commission, the leading accreditor of health care organizations in America. CTCA at Midwestern was recognized by The Joint Commission for exemplary performance in using evidence-based clinical processes that are shown to improve care for certain conditions.

CTCA at Midwestern is one of only 35 hospitals in Illinois earning the distinction of Top Performer on Key Quality Measures for attaining and sustaining excellence in accountability measure performance. CTCA at Midwestern was recognized for its achievement in surgical services. In 2012, the hospital celebrated its surgical capabilities with the opening of a 25,000 square foot surgical center.This new center provides the opportunity for cancer patients to benefit from expanded services in minimally invasive neurosurgery, Hyperthermic Intraperitoneal Chemoperfusion (HIPEC), Interoperative Radiation Therapy (IORT), orthopedic oncology and reconstructive surgery.

"Every day, we make a commitment to our patients that we will provide them with compassionate care that, above all else, is safe and effective," said President and CEO of CTCA at Midwestern Scott Jones, FACHE, MHA. "This is especially true for patients who seek oncology care for advanced surgical options that offer powerful, innovative therapy against cancer. That is why at CTCA at Midwestern we hold ourselves accountable to transparent quality reporting.We are honored to be recognized as a Joint Commission Top Performer on Key Quality Measures," said Jones.

As a Top Performer on Key Quality Measures, CTCA at Midwestern met criteria illustrating 1) cumulative performance of 95 percent or above across all reported accountability measures; 2) performance of 95 percent or above on each and every reported accountability measure where there are at least 30 denominator cases; and 3) at least one core measure set that has a composite rate of 95 percent or above, and (within that measure set) all applicable individual accountability measures have a performance rate of 95 percent or above.

"CTCA at Midwestern and all the Top Performer hospitals have demonstrated an exceptional commitment to quality improvement and they should be proud of their achievement," said President and CEO of The Joint Commission Mark R. Chassin, MD, FACP, MPP, MPH. "We have much to celebrate this year. Nearly half of our accredited hospitals have attained or nearly attained the Top Performer distinction. This truly shows that we are approaching a tipping point in hospital quality performance that will directly contribute to better health outcomes for patients."

In addition to being included in the recent release of The Joint Commission's "Improving America's Hospitals" annual report, CTCA at Midwestern will be recognized on The Joint Commission's Quality Check website (www.qualitycheck.org). The Top Performer program will be featured in the December issues of The Joint Commission Perspectives and The Source.

About Cancer Treatment Centers of America at Midwestern Regional Medical Center
Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center is a 73 bed specialty hospital dedicated to treating patients battling advanced and complex cancer.CTCA at Midwestern is nationally recognized for providing innovative and individualized cancer care and has been designated by the National Quality Measures for Breast Centers Program (NQMBC®) as a Certified Quality Breast Center of Excellence', ranking the hospital among the top centers in the country for quality breast cancer care. CTCA at Midwestern is the only Certified Breast Center of Excellence in Illinois, and one of only 41 nationally.As a member of the National Marrow Donor Program (NMDP) the hospital also offers a Stem Cell Transplant and Cell Therapy program that provides a full spectrum of transplantation services and advanced treatment options for hematologic cancers. CTCA at Midwestern is proud to use the latest technology to offer advanced treatment for cancer and is currently one of only a few hospitals in the nation to combine recent advances in brain mapping and navigation to perform minimally invasive brain surgery on hard to reach brain tumors.

SOURCE CTCA

© 2013 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.